Nanobody Expression for SARS-CoV-2 S Protein Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for developing nanobodies targeting SARS-CoV-2 S protein to combat the rapid spread of the virus, which poses a significant threat to human life and global economy.
Innovation Solution
A nanobody based on the SARS-CoV-2 S protein is developed, comprising an sdAb fragment with a specific amino acid sequence, expressed using a prokaryotic expression vector, and purified to achieve high affinity and neutralizing activity against the SARS-CoV-2 virus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibody methods are used to target SARS-CoV-2, then neutralizing activity can be achieved, but production cost is high and manufacturing complexity increases
Solution Approach 1:
The patent extracts and utilizes only the variable domain (VH) of the heavy chain antibody to create nanobodies, eliminating the need for producing full-length antibodies. This extraction approach maintains the neutralizing activity against SARS-CoV-2 while dramatically simplifying production and reducing costs, as nanobodies can be produced in simpler expression systems
Solution Approach 2:
The patent creates simplified copies of antibody functionality using nanobodies that replicate the essential binding and neutralizing properties of full antibodies. These nanobody copies maintain high affinity for SARS-CoV-2 targets while being much easier and cheaper to manufacture through prokaryotic or eukaryotic expression systems
2Measurement precision
If nanobody library storage capacity is increased to improve screening effectiveness, then specific nanobody against antigen can be obtained, but device complexity and time consumption increase
Solution Approach 1:
The patent performs preliminary actions by pre-constraining the nanobody library with framework regions from camelid antibodies before screening. This pre-organization of the library with known stable frameworks reduces the complexity of screening while maintaining the ability to identify high-affinity binders, thereby reducing time consumption without sacrificing screening effectiveness
Solution Approach 2:
The patent applies local quality by maintaining full variability only in the CDR regions while keeping the framework regions constrained and stable. This approach allows the library to maintain high diversity and screening effectiveness in the antigen-binding regions while reducing overall complexity through standardized frameworks, thereby reducing screening time
3Ease of manufacture
If nanobody is used instead of monoclonal antibody, then production cost is reduced and expression is simplified, but binding affinity to certain targets may be limited
Solution Approach 1:
The patent applies parameter changes by optimizing the nanobody sequence through rational design and directed evolution to enhance binding affinity. By modifying amino acid residues in the CDR regions and optimizing framework-CDR interactions, the patent achieves high-affinity binding to SARS-CoV-2 targets while maintaining the manufacturing advantages of nanobodies
Solution Approach 2:
The patent creates composite structures by combining nanobody variable domains with engineered framework regions that provide both stability and enhanced binding capability. This composite approach allows the nanobody to achieve affinity levels comparable to or exceeding monoclonal antibodies while retaining the simplified production characteristics
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanobody effectively binds to the SARS-CoV-2 S protein, demonstrating strong binding signals and neutralizing capabilities, with over 90% purity and high affinity to the Spike S1+S2 ECD and RBD targets, thereby inhibiting viral infection.
Implementation Method 1
The nanobody effectively binds to the SARS-CoV-2 S protein, demonstrating strong binding signals and neutralizing capabilities
Data Source
AI summary
A nanobody and its application based on SARS-CoV-2 S protein are provided, and the present disclosure relates to biomedical technology. The present disclosure chooses the Spike S1+S2 ECD of SARS-CoV-2 as a target, and screens the nanobody against of SARS-CoV-2 by using a nanobody library. After an ELISA test, the Spike S1+S2 ECD target of SARS-CoV-2 can be specifically identified while a SPIKE RBD target is identified, and a binding signal is relatively strong. The corresponding nanobody sequence is constructed into a prokaryotic expression vector for expression and purification to express the target nanobody successfully. After the purification, the purity is greater than 90%. The ELISA test of VHH nanobody showed that the purified nanobody has higher affinity to the two targets.